KRAS and neoplasm: SRGs are predominantly expressed in epithelial tumor cells, driving key oncogenic pathways such as epithelial-mesenchymal transition (EMT), KRAS signaling, and IL6-JAK-STAT3 activation, highlighting their contribution to tumor progression and invasiveness.